Show all News

We are working to develop our technology and commercialise MSC-based pharmaceuticals – find out more about our day-to-day work.

Bioceltix is entering an infant industry

All of the stem-cell-based biopharmaceuticals being developed by our company are designed to treat conditions caused by chronic inflammatory diseases. We are developing biopharmaceuticals to treat osteoporosis and atopic dermatitis in dogs, chronic inflammation of the oral cavity as well as gingivitis in cats, and medicines that help heal torn ligaments and treat conditions related to the lower limbs for horses. We talked more about our company, plans and the drugs we are developing in Puls Biznesu. 

Publication available only in Polish.

Wrote about us

Puls Biznesu

Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...

Article

Forbes- Incredibles

Forbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...

Article

Investors’ Zone

According to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...

Article

Portal Wrocław

Gazeta Wrocławska wrote about us: “Bioceltix is ​​working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...

Article

Mam Startup – summary 2021

We create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...

Article